Inventor · disambiguated record
Stacey Drabic
Also filed as: DRABIC STACEY · DRABIC STACEY V
10 granted patents·10 pending applications·23 citations·filing 2012–2025
86Inventor score
Top patents by PatentIndex Score
20 records- 0193US10457732B2Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2017·Granted Oct 29, 2019·10 cites·12 claims
- 0289USRE49908EBispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2021·Granted Apr 9, 2024·1 cites·43 claims
- 0389US11279759B2Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Mar 22, 2022·4 cites·19 claims
- 0487US2025074986A1Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 0583US10000553B2CD40L-specific TN3-derived scaffolds and methods of use thereofMEDIMMUNE LLC·Filed 2012·Granted Jun 19, 2018·6 cites·19 claims
- 0678US2023242619A1Compositions comprising a tn3 scaffold and methods of using the sameVIELA BIO INC·Filed 2022·Application pending·0 cites
- 0777US11104720B2Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunitVIELA BIO INC·Filed 2018·Granted Aug 31, 2021·1 cites·22 claims
- 0875US2023201346A1Binding molecules specific for il-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0975US2022251204A1Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 1074US11555062B2Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomerVIELA BIO INC·Filed 2021·Granted Jan 17, 2023·0 cites·39 claims
- 1173US10022443B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2015·Granted Jul 17, 2018·1 cites·17 claims
- 1273US2024270861A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1373US2024360223A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1472US2025257120A1Compositions comprising a tn3 scaffold and methods of using the sameVIELA BIO INC·Filed 2025·Application pending·0 cites
- 1567US11529415B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·0 cites·14 claims
- 1667US10588969B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·0 cites·14 claims
- 1760US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1855US2023257467A1Proteins binding nkg2d, cd16 and egfrDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1954US2021260159A1CD40L-Fc FUSION POLYPEPTIDES AND METHODS OF USE THEREOFMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 2052US10975155B2CD40L-Fc fusion polypeptides and methods of use thereofMEDIMMUNE LLC·Filed 2017·Granted Apr 13, 2021·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Stacey Drabic files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →